Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03925324 · ClinicalTrials.gov registry record · Phase 2
Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03925324 is a Phase 2 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 4 participants.
The verdict
NCT03925324, a Phase 2 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.
Interventions
- OTHER Placebo
- BIOLOGICAL Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2021-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03925324
The ClinicalTrials.gov registry entry for NCT03925324 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03925324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03925324 about?
NCT03925324 is a clinical study titled "Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device". A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.
What is the current status of trial NCT03925324?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-05-03. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT03925324?
The interventions under investigation include: Placebo (OTHER), Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03925324?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.